News coverage about CombiMatrix (NASDAQ:CBMX) has trended somewhat positive recently, according to Accern. The research group identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. CombiMatrix earned a media sentiment score of 0.12 on Accern’s scale. Accern also gave media stories about the medical research company an impact score of 45.4077638389534 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
CombiMatrix (NASDAQ:CBMX) traded down $0.20 during trading on Tuesday, hitting $6.25. 51,800 shares of the stock were exchanged, compared to its average volume of 119,111. The company has a current ratio of 3.23, a quick ratio of 3.03 and a debt-to-equity ratio of 0.02. CombiMatrix has a fifty-two week low of $2.20 and a fifty-two week high of $8.20.
CombiMatrix (NASDAQ:CBMX) last posted its earnings results on Monday, November 6th. The medical research company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.03. The business had revenue of $4.01 million for the quarter, compared to analyst estimates of $4.19 million. CombiMatrix had a negative net margin of 13.19% and a negative return on equity of 27.90%. During the same period last year, the business posted ($0.38) EPS. research analysts expect that CombiMatrix will post -0.59 EPS for the current year.
ILLEGAL ACTIVITY WARNING: “CombiMatrix (CBMX) Given Daily Media Impact Score of 0.12” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another domain, it was illegally stolen and republished in violation of US and international copyright & trademark law. The original version of this story can be accessed at https://www.dispatchtribunal.com/2017/12/05/combimatrix-cbmx-given-daily-media-impact-score-of-0-12.html.
CombiMatrix Company Profile
CombiMatrix Corporation is a provider of molecular diagnostic solutions. The Company specializes in pre-implantation genetic screening, miscarriage analysis, prenatal diagnosis and pediatric developmental disorders, offering deoxyribonucleic acid-based testing for the detection of genetic abnormalities, which cannot be identified through traditional methodologies.
Receive News & Ratings for CombiMatrix Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CombiMatrix Corporation and related companies with MarketBeat.com's FREE daily email newsletter.